The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer

被引:9
作者
Bai, Xiaojing [1 ,2 ]
Jiang, Yumei [1 ,2 ]
Zhang, Xinwei [1 ,2 ]
Wang, Meiyu [3 ]
Tian, Juanhua [1 ]
Mu, Lijun [1 ]
Du, Yuefeng [1 ,2 ]
机构
[1] Xi An Jiao Tong Univ, Dept Urol, Affiliated Hosp 1, 277 Western Yanta Rd, Xian 710061, Shaanxi, Peoples R China
[2] Minist Educ, Oncol Res Lab, Key Lab Environm & Genes Related Dis, Xian 710061, Shaanxi, Peoples R China
[3] Xi An Jiao Tong Univ, Dept Imaging, Affiliated Hosp 1, Xian 710061, Shaanxi, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2020年 / 12卷
基金
中国国家自然科学基金;
关键词
total prostate-specific antigen; free prostate-specific antigen; prostate-specific antigen density; prostate cancer; benign prostatic hyperplasia; FREE ELECTROCHEMICAL IMMUNOSENSOR; DIGITAL RECTAL EXAMINATION; ULTRASOUND-GUIDED BIOPSY; MULTI-PARAMETRIC MRI; MAGNETIC-RESONANCE; HIGH-RISK; NG/ML; PSA; MEN; COMPLICATIONS;
D O I
10.2147/CMAR.S257769
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of this study was to explore the value of the prostate-specific antigen (PSA) levels, the ratio of free PSA to total PSA (fPSA/TPSA), the PSA density (PSAD), digital rectal examination (DRE), transrectal prostate ultrasound (TRUS), and multiparameter MRI (MP-MRI) in the differential diagnosis of benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Methods: From February 2016 to September 2019, data from 620 patients who underwent systematic transrectal ultrasound-guided prostate biopsy (STURS-PB) in our hospital were retrospectively collected, including the PSA levels, the fPSA/TPSA ratio, the PSAD, DRE, TRUS, MP-MRI, prostate volume, and other clinical data. Results: Among the 620 patients, 249 patients were in the PCa group, and 371 patients in the BPH group. The positive puncture rate was 40.16%. The positive predictive values of DRE, TRUS, mpMRI, and TPSA levels for PCa were 39.91%, 39.38%, 64.14%, and 41.57%, respectively; the sensitivity of these parameters was 37.35%, 51.41%, 74.69%, and 57.43%, respectively; and the specificity of these parameters was 62.26%, 46.90%, 71.97%, and 45.82%, respectively. When the TPSA concentration was in the range of 4-20 ng/mL, the positive puncture rate of STURS-PB was 23.18%, with a high rate of misdiagnosis. When the TPSA concentration was in the range of 4-20 ng/mL, the fPSA/ TPSA ratio was 0.15, the PSAD was 0.16, the comprehensive evaluation of PCa was optimal (the sensitivity of these parameters was 88.85% and 84.09%, respectively; the specificity was 80.17% and 67.29%, respectively; the positive predictive value was 57.41% and 51.39%, respectively). When the TPSA concentration >4 ng/mL, the fPSA/TPSA ratio <= 0.15 and the PSAD >= 0.16, the sensitivity, specificity, and correctness index of the PCa and BPH diagnosis were 80.54%, 82.75%, and 67.07%, respectively. Conclusion: When using DRE, TRUS, and MP-MRI to screen for PCa, MP-MRI has a relatively high sensitivity and specificity. Using these three thresholds (TPSA >4 ng/mL combined with an fPSA/TPSA ratio <= 0.15 and a PSAD >= 0.16) is significantly better than using TPSA levels alone for the differential diagnosis of PCa and BPH.
引用
收藏
页码:6821 / 6826
页数:6
相关论文
共 50 条
[21]   Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate [J].
Satoshi Otsubo ;
Akira Yokomizo ;
Osamu Mochida ;
Masaki Shiota ;
Katsunori Tatsugami ;
Junich Inokuchi ;
Seiji Naito .
World Journal of Urology, 2015, 33 :329-333
[22]   Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement [J].
Sundaresan, Vinaik M. ;
Smani, Shayan ;
Rajwa, Pawel ;
Renzulli, Joseph ;
Sprenkle, Preston C. ;
Kim, Isaac Y. ;
Leapman, Michael S. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (01) :41-48
[23]   The case for prostate cancer screening with prostate-specific antigen [J].
Andriole, Gerald ;
Djavan, Bob ;
Fleshner, Neil ;
Schroder, Fritz .
EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (12) :737-745
[24]   PROSTATE-SPECIFIC ANTIGEN IN SCREENING OF PROSTATE-CANCER [J].
CHU, TM .
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1994, 8 (05) :323-326
[25]   Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer [J].
Zou, Bing-Zi ;
Wen, Hong ;
Luo, Huan-Jia ;
Luo, Wan-Chao ;
Xie, Qi-Tong ;
Zhou, Meng-Ting .
IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (06) :2681-2687
[26]   Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer [J].
Bing-Zi Zou ;
Hong Wen ;
Huan-Jia Luo ;
Wan-Chao Luo ;
Qi-Tong Xie ;
Meng-Ting Zhou .
Irish Journal of Medical Science (1971 -), 2023, 192 :2681-2687
[27]   Is there an optimal prostate-specific antigen threshold for prostate biopsy? [J].
Stephan, Carsten ;
Miller, Kurt ;
Jung, Klaus .
EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (08) :1215-1221
[28]   Prostate-Specific Antigen Dynamics and Prostate Cancer Diagnosis [J].
Bartoletti, Riccardo .
EUROPEAN UROLOGY, 2009, 56 (05) :761-762
[29]   Application and optimization of prostate-specific antigen screening strategy in the diagnosis of prostate cancer: a systematic review [J].
Zhang, Zhengchao ;
Tian, Aimin ;
Che, Jizhong ;
Miao, Yandong ;
Liu, Yuanyuan ;
Liu, Yangyang ;
Xu, Yankai .
FRONTIERS IN ONCOLOGY, 2024, 13
[30]   Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer. [J].
Haese A. ;
Graefen M. ;
Huland H. ;
Lilja H. .
Current Urology Reports, 2004, 5 (3) :231-240